BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11433388)

  • 1. A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells.
    Chaux P; Lethé B; Van Snick J; Corthals J; Schultz ES; Cambiaso CL; Boon T; van der Bruggen P
    Eur J Immunol; 2001 Jun; 31(6):1910-6. PubMed ID: 11433388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.
    Chaux P; Vantomme V; Stroobant V; Thielemans K; Corthals J; Luiten R; Eggermont AM; Boon T; van der Bruggen P
    J Exp Med; 1999 Mar; 189(5):767-78. PubMed ID: 10049940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.
    Manici S; Sturniolo T; Imro MA; Hammer J; Sinigaglia F; Noppen C; Spagnoli G; Mazzi B; Bellone M; Dellabona P; Protti MP
    J Exp Med; 1999 Mar; 189(5):871-6. PubMed ID: 10049951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
    Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
    Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.
    Luiten RM; Demotte N; Tine J; van der Bruggen P
    Tissue Antigens; 2000 Jul; 56(1):77-81. PubMed ID: 10958359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
    Zhang Y; Chaux P; Stroobant V; Eggermont AM; Corthals J; Maillère B; Thielemans K; Marchand M; Boon T; Van Der Bruggen P
    J Immunol; 2003 Jul; 171(1):219-25. PubMed ID: 12817001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
    Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
    J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes.
    Luiten R; van der Bruggen P
    Tissue Antigens; 2000 Feb; 55(2):149-52. PubMed ID: 10746786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes.
    Schultz ES; Zhang Y; Knowles R; Tine J; Traversari C; Boon T; van der Bruggen P
    Tissue Antigens; 2001 Feb; 57(2):103-9. PubMed ID: 11260504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
    Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
    Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.
    Cecconi V; Moro M; Del Mare S; Sidney J; Bachi A; Longhi R; Sette A; Protti MP; Dellabona P; Casorati G
    Eur J Immunol; 2010 Jun; 40(6):1603-16. PubMed ID: 20306469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
    Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
    J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens.
    Sato N; Nabeta Y; Kondo H; Sahara H; Hirohashi Y; Kashiwagi K; Kanaseki T; Sato Y; Rong S; Hirai I; Kamiguchi K; Tamura Y; Matsuura A; Takahashi S; Torigoe T; Ikeda H
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S86-90. PubMed ID: 10950155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.
    Consogno G; Manici S; Facchinetti V; Bachi A; Hammer J; Conti-Fine BM; Rugarli C; Traversari C; Protti MP
    Blood; 2003 Feb; 101(3):1038-44. PubMed ID: 12393675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAGE-A3(161-175) contains an HLA-DRbeta4 restricted natural epitope poorly formed through indirect presentation by dendritic cells.
    Marturano J; Longhi R; Casorati G; Protti MP
    Cancer Immunol Immunother; 2008 Feb; 57(2):207-15. PubMed ID: 17628799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.
    Duffour MT; Chaux P; Lurquin C; Cornelis G; Boon T; van der Bruggen P
    Eur J Immunol; 1999 Oct; 29(10):3329-37. PubMed ID: 10540345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide.
    Harada M; Gohara R; Matsueda S; Muto A; Oda T; Iwamoto Y; Itoh K
    J Immunol; 2004 Feb; 172(4):2659-67. PubMed ID: 14764741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.